Bauermeister, J.A., Golub, S., Hosek, S. et al. Stated Choice Methods in Long-Acting and Extended-Release HIV Technologies: A Scoping Review of Methodological Practices and Translational Utility. Curr HIV/AIDS Rep 23, 35 (2026). https://doi.org/10.1007/s11904-026-00804-0
Long-acting and extended-release (LA/ER) formulations are reshaping the HIV prevention and treatment landscape [1]. Injectable antiretroviral therapies, subcutaneous implants, oral tablets/pills, and other sustained-delivery platforms hold the potential to address longstanding barriers to adherence and persistence, barriers that have proven particularly consequential for populations disproportionately affected by HIV who face structural inequities in healthcare access [2, 3]. The recent approval of long-acting injectable formulations and the anticipated approval of extended-release pill formulations for both treatment and prevention have intensified the need to understand how individuals and providers evaluate and choose among them [4, 5].
Translating LA/ER technologies from clinical efficacy to real-world effectiveness requires more than demonstrating that a product works; it requires understanding how people will use it, deliver it, and make decisions about it. Product developers, regulatory agencies, and implementation planners increasingly rely on “stated choice” methods, including discrete choice experiments (DCEs), conjoint analysis, and best–worst scaling approaches such as MaxDiff, to generate this evidence [5,6,7,8]. Grounded in random utility theory, stated choice approaches allow investigators to model which product (e.g., dosing frequency) and service delivery (e.g., delivery location) attributes matter most to potential users and to examine how trade-offs between attributes vary across individuals and priority population subgroups [9,10,11,12]. This results in information that can be directly actionable for product design, regulatory decision-making, and implementation planning [13,14,15,16]. By requiring users to make choices about trade-offs between attributes, these approaches yield quantifiable measures of the importance of each attribute relative to others. Thus, these methods offer a rigorous framework for quantifying the relative importance intended users place on specific product and service characteristics, such as dosing frequency, route of administration, side effects, clinic visit requirements, delivery location, and cost.